Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Up 29.6% in February

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 26,700 shares, an increase of 29.6% from the January 31st total of 20,600 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 42,200 shares, the short-interest ratio is currently 0.6 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP boosted its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 45.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,226 shares of the company’s stock after purchasing an additional 7,886 shares during the period. Dimensional Fund Advisors LP owned about 0.30% of Lisata Therapeutics worth $75,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Stock Performance

LSTA stock remained flat at $2.15 during midday trading on Tuesday. The company’s stock had a trading volume of 6,376 shares, compared to its average volume of 55,131. The company’s 50-day moving average is $2.92 and its 200-day moving average is $2.90. Lisata Therapeutics has a twelve month low of $2.14 and a twelve month high of $4.20. The stock has a market cap of $18.05 million, a PE ratio of -0.86 and a beta of 1.14.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.21. The business had revenue of $1.00 million during the quarter. Research analysts expect that Lisata Therapeutics will post -2.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a research report on Wednesday, December 11th.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.